OncoMatch

OncoMatch/Clinical Trials/NCT05968326

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

Is NCT05968326 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Autogene cevumeran and Atezolizumab for adenocarcinoma, pancreatic ductal.

Phase 2RecruitingGenentech, Inc.NCT05968326Data as of May 2026

Treatment: Autogene cevumeran · Atezolizumab · mFOLFIRINOX — The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Biomarker criteria

Excluded: DPYD complete deficiency (homozygous or compound heterozygous mutations associated with DPD deficiency)

Known complete dihydropyrimidine dehydrogenase (DPD) deficiency including homozygous or compound heterozygous mutations of DPYD genetic locus associated with DPD deficiency

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: adjuvant, neoadjuvant, or induction treatment

Prior adjuvant, neoadjuvant, or induction treatment for pancreatic cancer

Lab requirements

Blood counts

Adequate hematologic function

Kidney function

Adequate end-organ function

Liver function

Adequate end-organ function

Adequate hematologic and end-organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • USC Norris Comprehensive Cancer Center · Los Angeles, California
  • USC Norris Cancer Center · Newport Beach, California
  • University of California, San Francisco (UCSF) · San Francisco, California
  • University of California Los Angeles · Santa Monica, California
  • St. Francis Hospital and Medical Center · Hartford, Connecticut

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify